OraSure Technologies Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
OraSure Technologies Bundle
Actionable Strategy Starts Here
OraSure’s BCG Matrix preview hints at which diagnostic products are pulling weight and which need a rethink—some look like Stars, others lean toward Cash Cows or Question Marks. Want the full picture with quadrant-by-quadrant reasoning, revenue and market-share data, and clear strategic moves? Purchase the complete BCG Matrix for a ready-to-use Word report plus an Excel summary that lets you present, decide, and act fast. Get instant access and stop guessing where to allocate your next dollar.
Stars
OraQuick HIV self-test (global)
OraQuick HIV self-test remains a Star in 2024, holding leading procurement positions across LMIC programs due to WHO prequalification and strong brand recognition in global tenders. It commands a high share of the expanding HIV self-testing channel while burning cash on scale-up, distribution, and demand-generation. The runway to a cash cow is tangible if investment continues in access, awareness, and logistics.
Saliva DNA collection (Oragene) for genomics
Saliva DNA collection (Oragene) sits in Stars: market-leading with research programs and select DTC players, supported by precision medicine budgets and cohort growth (All of Us >541,000 participants by 2024). The category is competitive yet OraSure kits remain default in many large studies while DTC channels have sold >30 million kits cumulatively. Growth is brisk, requiring working capital and promotional spend; double down on enterprise deals and clinical-grade validations to solidify share.
Microbiome collection (OMNIgene)
Microbiome collection (OMNIgene) sits in Stars: translational trials and biobanking are scaling fast, with the microbiome market estimated by multiple industry reports to grow at high-teens CAGR through the late 2020s. OraSure leverages a recognized kit portfolio and sticky workflows from the DNA Genotek OMNIgene line, supporting widespread trial use and sample stability. High growth requires significant burn on studies, KOL engagement, and regulatory pathways, but preserving land‑standard status as the space matures makes continued investment strategically justified.
Oral-fluid drug testing for workplace screening
Regulatory momentum and rising employer adoption are pushing oral-fluid workplace screening into a higher-growth segment; OraSure’s two decades of Intercept oral-fluid expertise supports superior usability and chain-of-custody compared with many point-of-collection alternatives.
Growth in oral-fluid testing is outpacing some lab-based urine panels, enabling share gains for OraSure if it leverages compliance credentials and expands national-account penetration.
- Regulatory tailwinds: adoption rising
- Competitive edge: oral-fluid chain-of-custody
- Market dynamics: faster growth vs some lab methods
- Strategic focus: push compliance credentials + national accounts
HIV professional POC programs
HIV professional POC programs remain Stars for OraSure in 2024 as community clinics and outreach expand rapid screening and demand for same‑visit results grows. OraSure’s training networks and established OraQuick footprint drive consistent testing volume and market access where speed‑to‑result is decisive. Continued funding for field support and partnerships is critical to secure tenders and sustain growth.
- 2024 focus: expand clinic/outreach screening
- Strength: OraQuick footprint + training networks
- Value prop: leader in rapid speed-to-result
- Action: fund field support & partnerships to lock tenders
Star portfolio: HIV lead, DTC kits 30M+; microbiome high‑teens CAGR
OraQuick remains a Star in 2024, leading LMIC procurement and the HIV self-test channel while needing spend to scale to cash‑cow. Oragene/DTC kits >30 million cumulative sales and All of Us >541,000 participants by 2024 keep Oragene a Star. OMNIgene rides a microbiome market growing at high‑teens CAGR, justifying continued investment to hold land‑standard status.
| Product | 2024 signal | Key metrics |
|---|---|---|
| OraQuick | Star | LMIC procurement lead |
| Oragene | Star | >30M DTC kits; All of Us >541k |
| OMNIgene | Star | Microbiome high‑teens CAGR |
What is included in the product
Detailed Word Document
In-depth BCG analysis of OraSure's portfolio, identifying Stars, Cash Cows, Question Marks and Dogs with clear investment guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for OraSure clarifies portfolio pain points for fast C-level decisions
Cash Cows
Hepatitis C rapid antibody test
Hepatitis C rapid antibody test delivers steady cash flow from mature demand, with public health screening programs in 2024 still targeting millions annually (US burden ~2.4 million chronic infections; global chronic infections ~58 million). High gross margins after distribution scale and modest promotional spend make it a reliable profit center that funds pipeline R&D. Prioritize manufacturing efficiency and defend pricing to preserve cash generation.
Established DTC ancestry/research saliva kits
By 2024 the DTC ancestry boom cooled to low single-digit annual growth, but volumes remain stable and predictable, supporting recurring demand. OraSure remains a preferred supplier with validated workflows and regulatory-compliant assays, enabling consistent unit economics. Cash cow characteristics: low growth, solid margin, minimal upkeep. Continue to milk with light innovation and supply-chain tune-ups to preserve profitability.
Intercept oral-fluid drug test (legacy accounts)
Intercept oral-fluid drug test legacy accounts remain entrenched in employer and government contracts and delivered steady cash flow, reporting roughly $35 million in revenue in fiscal 2024 per company disclosures, reflecting low-double-digit percent contribution to OraSure’s topline.
High switching costs, documented compliance history and enrollment in long-term programs make these accounts sticky, reducing churn and preserving margin.
Not a growth driver, it pays the bills; focus on optimizing COGS and operations and avoid heavy promotional spend that would compress returns.
Specimen stabilization OEM lines
Specimen stabilization OEM lines are white-label kit components that ride customers’ installed bases, enabling incremental throughput lifts via upgrades without heavy marketing. They generate steady cash with limited field support, lowering cost-to-serve while protecting SLAs and expanding basket size through add-on consumables and service agreements.
- White-label kits leverage installed base
- Upgrades raise throughput, minimal marketing
- High cash conversion, limited field support
- Protect SLAs and expand basket size
Alcohol screening products (e.g., Q.E.D.)
Alcohol screening products such as Q.E.D. sit squarely in Cash Cows: steady occupational and law‑enforcement demand underpins predictable reorder cycles. The category is mature with minimal growth, delivering recurring cash flows with limited incremental capex. Maintain lean operations and protect distribution reach to sustain margin contribution.
- Steady occupational and law‑enforcement demand
- Mature category, minimal growth
- Recurring cash with limited capex
- Keep lean; preserve distribution reach
Cash cows fund R&D: protect margins with tight COGS, SLAs and minimal promotion
Cash cows (Hep C rapid test; DTC ancestry stable; Intercept drug test ~$35M 2024; Q.E.D. alcohol screens; specimen stabilization OEM) generate steady, low-growth high-margin cash supporting R&D; focus on COGS, SLAs, minimal promo.
| Product | 2024 Rev | Growth |
|---|---|---|
| Hep C rapid test | steady (public screening) | mature |
| DTC ancestry | low-single-digit growth volumes | stable |
| Intercept drug test | $35M | stable |
What You’re Viewing Is Included
OraSure Technologies BCG Matrix
The file you're previewing on this page is the exact BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just a fully formatted, analysis-ready document designed for strategic clarity. It’s crafted with market-backed insight and delivered straight to your inbox. Once bought, it’s immediately editable, printable, and presentation-ready for your team or clients.
Dogs
COVID-19 rapid antigen (InteliSwab)
Post-2022 demand collapse after the US federal free-test program ended in 2022 has left InteliSwab on crowded shelves and facing severe price erosion; market growth is essentially zero by 2024 and OraSure’s share is slipping in retail and public channels. Keeping InteliSwab on life support is a cash trap; recommend winding down SKUs or exiting the segment.
Niche legacy diagnostics with low utilization
Small, shrinking segments that tie up inventory and service time, with legacy oral fluid diagnostics showing low utilization and declining orders. Little differentiation and minimal pull-through mean these products contribute marginally to revenue and are break-even at best. Recommend pruning SKUs and redeploying R&D and commercial resources to higher-growth rapid molecular and infectious disease segments.
Discontinued tender geographies
Discontinued tender geographies in 2024 saw funding cycles end and renewals stall across several public health markets, leaving OraSure with ongoing support costs while test volumes declined. This classic trap dynamic erodes margin as fixed service and logistics expenses persist despite shrinking demand. Recommend divest or sunset contracts cleanly to stop cash burn and reallocate resources to growing markets.
Overlapping older collection formats
Overlapping older collection formats remain listed in OraSure's catalog as of 2024, creating SKUs that add handling and regulatory burden without delivering incremental margin; customers have largely migrated to newer kits. Rationalizing legacy SKUs will cut complexity-driven costs and streamline supply chain.
- Remove redundant SKUs
- Consolidate to current kits
- Reduce carrying and QC costs
Non-core accessories
Dogs:
Non-core accessories
Low-volume add-ons that don’t drive kit adoption; in 2024 these SKUs produced minimal uplift to core diagnostics and imposed outsized inventory risk. Hard to price for profit given low order frequency and thin margins; eliminate or bundle selectively to cut carrying costs and free SKU space.- Low volume
- High inventory risk
- Hard to price
- Eliminate or bundle
Post-2022 free-test collapse left antigen swab glut; rationalize SKUs, bundle accessories
Post-2022 free-test collapse left InteliSwab inventory-heavy; market growth essentially 0% by 2024 and retail/public share slipping. Legacy oral-fluid kits and non-core accessories delivered minimal uplift and tie up working capital. Recommend SKU rationalization, bundle or sunset low-volume accessories to stop cash burn and redeploy resources to higher-growth molecular segments.
| Item | 2024 status | Impact | Action |
|---|---|---|---|
| InteliSwab | Inventory glutted | Low demand | Wind down |
| Accessories | Low volume | High carry cost | Eliminate/bundle |
Question Marks
At-home STI self-collection partnerships
At-home STI self-collection sees fast-growing interest in a fragmented, competitive field — US STI cases hit roughly 2.5 million in 2022 (CDC), underscoring demand. Early volumes are lumpy and marketing-heavy, with high customer-acquisition costs. With payer coverage and strong clinical validation it could flip to a star; recommend test-and-invest via targeted pilots focused on high-prevalence regions and payer partnerships.
Liquid biopsy/cfDNA stabilization
Liquid biopsy/cfDNA stabilization addresses a high-growth oncology workflow in a market estimated at about 6.7 billion USD in 2024 with ~14% CAGR, but the field is crowded and technically demanding. Regulatory and pivotal trial costs routinely reach 50–200 million USD, raising the bar for new entrants. Successful placements in large trials can expand clinical share rapidly, sometimes 20–40% of addressable tests. Recommend focused co-development deals to de‑risk spend and accelerate adoption.
Wastewater and environmental surveillance kits
Wastewater and environmental surveillance kits sit in Question Marks for OraSure as public health interest resurged in 2024 but long-term cadence remains unclear. OraSure can repurpose collection tech and scale pilots, yet procurement has been episodic and tied to short-term grants. The business is cash-hungry with uncertain returns, so probe selectively and avoid a broad rollout.
Respiratory panel sampling beyond COVID
Respiratory panel sampling beyond COVID sits as a Question Mark for OraSure: strong seasonal surges (testing demand often spikes ~2–3x in peak months) create clear revenue upside, but OraSure currently holds low market share and faces high clinician and lab education costs.
If panels are integrated into clinical pathways and reimbursement, growth could accelerate rapidly; priority: partner with reference labs (e.g., regional labs handling >50% of outpatient testing) before scaling.
- Seasonal opportunity: demand spikes ~2–3x
- Current position: low share, high education cost
- Growth trigger: clinical pathway integration + reimbursement
- Go-to-market: partner with reference labs first
Digital integration and data services
Start with anchors in top accounts: digital integration adds stickiness to OraSure kits and can unlock enterprise deals, but monetization remains unproven and requires meaningful software investment. Enterprise sales cycles typically lengthen (12–24 months) and demand pilot-to-scale proofs; if digital capability becomes a buying criterion the upside is substantial given the digital health market >300B in 2024.
- Adds kit stickiness and enterprise entry
- Monetization unproven; needs software spend
- Longer sales cycles (12–24 months)
- High upside if it becomes buying criterion
Pilot-first approach: payer deals and co-devs to win high-growth STI and liquid biopsy markets
Question Marks: at-home STI (US ~2.5M cases in 2022) and liquid biopsy (global market ~$6.7B in 2024, ~14% CAGR) show high growth but high CAC, regulatory and trial costs; wastewater and respiratory panels have episodic demand; digital adds stickiness but lengthy 12–24m sales cycles. Recommend targeted pilots, payer partnerships, co-development and reference-lab anchors.
| Segment | 2024 metric | CAGR/risk | Near-term action |
|---|---|---|---|
| At-home STI | US demand signal: 2.5M cases (2022) | High CAC | Targeted pilots, payer deals |
| Liquid biopsy | $6.7B market (2024) | ~14% CAGR; $50–200M trials | Co-dev deals |
| Wastewater/Respiratory | Resurgent 2024 interest | Episodic procurement | Selective pilots, lab partners |